Financial Daily from THE HINDU group of publications
Tuesday, Nov 23, 2004
Marketing - New Products & Services
Industry & Economy - Health
Ranbaxy launches new drug for urological disorder
New Delhi , Nov. 22
RANBAXY Laboratories Ltd today announced the launch of its benign prostatic hyperplasia (BPH) formulation, branded Flotral (Alfuzosin). It is being launched for the first time in the Indian market.
This prescription medicine provides effective relief from signs and symptoms of BPH, a urological disorder, caused due to the enlargement of the prostate gland and commonly afflicts the ageing male population.
Flotral, is a once-a-day medication, developed using the Novel Drug Delivery System (NDDS) technology platform, resulting in better patient compliance.
Mr Sanjeev I. Dani, Regional Director - India, said in a statement, "The launch of Flotral further expands Ranbaxy's key strategic product portfolio and establishes the company's commitment to build its urology franchise through its competitive edge technology of NDDS."
Meanwhile, the pharmaceutical company is planning to restructure its business by exiting from its non-core segments such as animal healthcare, diagnostics and fine chemicals.
These account for close to Rs 125 crore of the company's turnover.
When contacted Ranbaxy officials "refused to comment on market rumours".
According to an analyst tracking the company, "The decision to hive off the non-core business will enable the company to focus on its core pharmaceuticals business. Except for the Fine Chemicals business, the company may be of the view that there are no synergies with the other business, though these segments may demand dedicated resources."
Stories in this Section
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2004, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line